Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

NCT01890694 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Hyponatremia

Interventions

DRUG: Tolvaptan
DRUG: Placebo
BEHAVIORAL: Hepatic Encephalopathy Assessment
BEHAVIORAL: Quality of Life Assessment
BIOLOGICAL: Vital signs
BIOLOGICAL: Blood laboratory tests
PROCEDURE: Ascites Evaluation
PROCEDURE: Edema

Sponsor

NYU Langone Health

Collaborators

[object Object]